Mucolipidosis Type II Secondary to GNPTAB Gene Deletion from India
Dear Sir, Mucolipidosis II (ML II) is a rare autosomal recessive disorder of lysosomal metabolism. It has often been clinically misdiagnosed as mucopolysaccharidosis. ML II is characterized by developmental delay, short stature, coarse facial features, and dysostosis multiplex. [1] We are reporting 9-month-old girl born to a second degree consanguineously married couple presented with developmental delay and noisy breathing. Examination revealed coarse facies, thick eyebrows, hypertelorism, bilateral corneal clouding, pectus excavatum, and kyphosis. There was hepatosplenomegaly but no cherry red spot. On investigations, thyroid function test and urine glycosaminoglycans were normal. Skeletal survey shows kyphosis of dorsal spine. Magnetic resonance imaging brain shows mild cerebral atrophy. Enzyme analysis in plasma shows elevated, alpha-mannosidase12,970 (normal: 20-120)-nmol/h/ml, alpha-fucosidase-6624 (normal: 90-610)-nmol/h/ml, and beta-hexosaminidase-T-23090 (normal: 620-4990) nmol/h/ml. High levels are suggestive of ML II/III. GNPTAB gene testing revealed a homozygotic deletion in exon 19 (c_3503_3504delTC). Based on severe MPS phenotype in early infancy, enzyme assay, and genetic testing, we diagnosed the case as ML II.
ML II is caused by deficiency of N-acetylglucosmine -1-phosphottransferase. This enzyme deficiency can produce two different phenotypes, ML II and ML III (pseudo-Hurler polydystrophy). [2] ML II and III differ in age of onset with ML II being present at birth and ML III starting clinical symptoms between 3 and 5 years of age. ML II causes severe intellectual disability, coarse facial features, skeletal abnormalities, and an early death during first decade. ML III is a late onset with variations in intellectual disability (normal to decreased), skeletal abnormalities which are prominent and these individuals may live for a number of decades. Based on above differences, we considered possibility of ML II in our child. [3] We excluded MPS based on early infancy presentation and absent of glycosaminoglycans in the urine. We ruled out congenital hypothyroidism based on normal thyroid function tests. We also excluded GM1 gangliosidosis and Sialidosis as child had no startle response, epilepsy, and cherry red spot in the fundus. Cury et al. reported mutation c_3503_3504delTC located in exon 19 was most common mutation (n = 11/24) in ML II and III in Brazil. [4] This mutation from Indian subcontinent is useful for the molecular diagnosis of ML II in India.
ML II should be considered as one of the differential diagnoses in patients presenting in early infancy with MPS phenotype. ML II is differentiated from ML III based on severe and early presentation in former.
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CDKL-5 Encephalopathy in an Indian Girl: Partial Response to the Modified Atkins Diet
Dear Sir, CDKL5-epileptic encephalopathy (EE) is an infantile-onset, X-linked catastrophic epilepsy, with intractable seizures accompanied by severe developmental delay, deceleration of head growth, and autistic traits in some patients. We describe a 3-years-old female child with CDKL5-EE who showed partial response to the modified Atkins diet.
This child presented at 2 years of age with a history of global developmental delay and seizures since 2 months of age. The perinatal period was uneventful. Seizures were generalized tonic and hypomotor, multiple times a day. She had failed phenobarbitone, phenytoin, valproate, carbamazepine, levetiracetam, topiramate, clobazam, and zonisamide. She had also failed therapeutic trials of pyridoxal phosphate, folinic acid, and biotin. She had not achieved social smile, head control, grasping, or vocalization. She also had poor eye contact and had stereotypies, microcephaly, and central hypotonia.
Investigations revealed a normal brain magnetic resonance imaging. The electroencephalogram showed multifocal spike-wave discharges. The metabolic testing (blood ammonia, arterial lactate, blood acylcarnitine profile, urinary organic acids) revealed no abnormalities. There was no cerebrospinal fluid hypoglycorrhachia.
In view of the clinical profile, a possibility of CDKL5 mutation was considered. Genetic testing for CDKL-5 mutations was performed as previously described. [1] All coding exons of CDKL5-gene were polymerase chain reaction amplified from genomic DNA and cycle sequenced in both forward and reverse directions. Mutation analysis revealed a novel heterozygous c. 529T>C nucleotide substitution leading to an amino acid change (p.Tyr177His), confirming the diagnosis of a CDKL5-encephalopathy. This mutation was not reported either in the HGMD professional 2016.1 database (Biobase, Qiagen, Hilden, Germany) or in the ExAC dataset (http://exac.broadinstitute.org).
As the child had failed multiple antiepileptic drugs (AEDs), she was started on the modified Atkins diet with carbohydrates limited to 10 g/day. There was no calorie, protein, or fluid restriction. Fats were actively encouraged. Within 1 week of starting the diet, there was a 60% reduction in seizure frequency (moderate urinary ketosis) and some improvement in alertness as well. At 1 year on the diet, the seizure frequency has significantly reduced from several times a day to 2-3 per week. However, there has been no improvement in autistic features or developmental milestones. There have been no significant side effects and she has tolerated the diet well.
Recently, Müller et al. reported the results of a retrospective evaluation of low long-term efficacy of AEDs and ketogenic diet (KD) in 39 patients with CDKL5-EE. [2] In the study, the authors found an overall low response to both AEDs and KD in the long-term. Only 2/12 patients had a significant seizures reduction during KD for more than 6 months and one of them
